Introduction
Interleukin(IL)-23p19-inhibitors are increasingly used in immune-mediated inflammatory diseases (IMIDs), particularly inflammatory bowel disease (IBD). Almost half of patients show inadequate response, partly due to pharmacokinetic (PK) variability. However, a comprehensive overview of their PK parameters is lacking, limiting understanding of population variability.
Aims & Methods
This systematic review assessed the PK of IL-23p19-inhibitors in healthy subjects, IBD, psoriasis, psoriatic arthritis and pustular/erythrodermic psoriasis. A systematic literature search was performed in PubMed and Embase on June 16 2025. Studies were screened by two independent researchers. Quality of evidence was assessed using the Cochrane risk-of-bias 2 tool and the Clinical Pharmacokinetic Study Checklist.
Results
A total of 21 studies were included (risankizumab n=9, guselkumab n=6, tildrakizumab n=3, mirikizumab n=3), covering healthy subjects, psoriasis, psoriatic arthritis, Crohn’s disease (CD), ulcerative colitis (UC) and pustular/erythrodermic psoriasis. Six studies addressed CD and three addressed UC, with PK data available for risankizumab (CD:1,392; UC:1,394) and mirikizumab (UC:1,362 adults, 26 paediatrics). No PK studies of guselkumab in IBD and mirikizumab in CD were identified. Notably, only one study focused on a distinct IBD population, specifically mirikizumab for paediatric UC. Moreover, optimal dosing strategies (particularly in paediatric and refractory populations) remained largely undefined. Based on our analysis, the following key PK findings were revealed (Table 1). First, for risankizumab, dose-normalized maximum concentration and area under the concentration (AUC)‑time curve over a dosing interval, along with central and peripheral volume of distribution (Vp) and clearance were generally similar across CD and UC. Second, patients with CD and UC demonstrated increased risankizumab trough levels over consecutive dosing intervals, while an opposite trend was observed across dosing regimens for other IMIDs. Third, Vp was generally lower in patients with CD and UC compared to patients with psoriasis who received risankizumab. Fourth, paediatric patients with UC who received mirikizumab showed an interinvidual variability in SC bioavailability of 77.6% (95%CI 24.7–119.0). Finally, covariate analysis revealed that albumin in UC was relevant to risankizumab PK. No covariates were yet reported to have a clinically meaningful effect on guselkumab or mirikizumab PK in IBD.
Table 1. Data extraction of population PK parameters of risankizumab.
Article
| Population
| PK model
| Cmax
| Ctrough
| AUC
| Vd
| CL
| Covariates
|
|---|
Suleiman and Khatri et al. (2019) (1) | Moderate to severe plaque PsO and moderate to severe CD.
| Two-compartment model.
| NR.
| NR.
| NR.
| Vc: 5.66 (RSE 7%) L
IIV: 55 (RSE 6%)
Vp,: 3.43 (RSE 5%) L
IIV: 35 (RSE 5%)
| 0.30 (RSE 3%) L/day
IIV: 37 (RSE 4%) L/day
Q: 0.33 (RSE 7%) L/day
| CLBW: 0.93 (RSE 10%) Vc_BW and Vp_BW 0.99 (RSE 11%)
CLALB: 1.54 (RSE 8%) Only BW had clinically relevant effect, but near the lower bound.
|
Suleiman and Minocha et al.(2019) (2) | Healthy subjects and moderate to severe plaque PsO.
| Two-comparment model.
| NR.
| Week 16: 2.48 ± 1.35 µg/mL
Week 52: 1.91 ± 1.17 µg/mL
| NR.
| Vc: 4.86, (RSE 3.8%) L
Vp: 4.25 (RSE 25%) L
IIV: 34 (RSE 6.6%)
| 0.243 (RSE 1.8%) L/day
Q: 0.656 (RSE 3.7%) L/day
IIV: 24 (RSE 3.6%)
| CLBW: 0.933 (RSE 3.3%)
Vc_BW: 1.17 (RSE 7.2%)
CLALB: − 0.715 (RSE 10.6%)
CLcreatinine: − 0.253 (RSE 10.2%)
CLCRP: 0.044 (RSE 10.5%)
VP_BW: 0.377 (RSE 12.0%)
Proportional increase in CL (43%) for an ADA titer ≥ 128: 0.428, (RSE 5.1%)
BW> 100 kg were predicted to have 30% lower exposures, Cmax and AUCτ than BW < 100 kg when administered 150 mg SC at weeks 0 and 4 and q12w.
|
Khatri et al. (2019) (3) | Healthy subjects, severe chronic plaque PsO, GPP and EP.
| Two-compartment model with first-order absorption and elimination.
| NR.
| Moderate to severe plaque PsO 75 mg SC week 4: Mean 3.52 (CV 36) µg/mL Moderate to severe plaque PsO 150 mg SC week 4: Mean 6.75 (CV 35) µg/mL
Moderate to severe plaque PsO 75 mg SC week 16: Mean 1.40 (CV 57) µg/mL
Moderate to severe plaque PsO 150 mg SC week 16: Mean 2.53 (CV 54) µg/mL
Moderate to severe plaque PsO 75 mg SC week 28: Mean 1.29 (CV 62) µg/mL
Moderate to severe plaque PsO 150 mg SC week 28: Mean 2.25 (CV 49%) µg/mL
Moderate to severe plaque PsO 75 mg SC week 40: Mean 1.23 (CV 80%) µg/mL
Moderate to severe plaque PsO 150 mg SC week 40: Mean 2.18 (CV 50%) µg/mL
Moderate to severe plaque PsO 75 mg SC week 52: Mean 1.08 (CV 54%) µg/mL
Moderate to severe plaque PsO 150 mg SC week 52: Mean 2.07 (CV 60%) µg/mL
GPP or EP 75 mg SC week 4: Mean 3.37 (CV 21%) µg/mL
GPP or EP 150 mg SC week 4: Mean 7.25 (CV 76%) µg/mL
GPP or EP 75 mg SC week 16: Mean 1.02 (CV 37%) µg/mL
GPP or EP 150 mg SC week 16: Mean 2.66 (CV 103%) µg/mL
GPP or EP 75 mg SC week 28: Mean 0.962 (CV 53%) µg/mL
GPP or EP 150 mg SC week 28: Mean 2.89 (CV 72%) µg/mL
GPP or EP 75 mg SC week 52: Mean 0.69 (CV 59%) µg/mL
GPP or EP 150 mg SC week 52: Mean 1.96 (CV 64%) µg/mL
| NR.
| Vc: 4.87 (RSE 3.8%) L
IIV: 0.111 (95% CI 0.053– 0.154)
VP: 4.25, (RSE 2.0%) L
| 0.244 (%RSE 1.8%) L/d IIV: 0.055 (95% CI 0.039– 0.067)
Q: 0.648 (%RSE 3.7%) L/d
| CLBW: 0.935 (RSE 3.1%)
VC_BW: 1.18 (RSE 6.9%)
CLALB: –0.717 (RSE 10.2)
CLcreatinine: –0.242 (RSE 10.1%)
CLCRP: 0.044, (RSE 10.1%)
VP_BW: 0.360, (RSE 12.3%)
Proportional increase for CL for ADA titer > 128: 0.431 (RSE 5.0%)
|
Thakre et al. (2022) (4) | Healthy subjects and active PsA.
| Two-compartment model.
| First dosing Interval (150 mg SC w0–4): 9.63 ± 3.05 µg/mL
Second dosing interval (150 mg SC w4–16): 14.7 ± 5.02 µg/mL
Third dosing interval (150 mg SC w16–28): 11.6 ± 4.36 µg/mL
| First dosing Interval (150 mg SC w0–4): 5.95 ± 2.09 µg/mL
Second dosing interval (150 mg SC w4–16): 2.32 ± 1.55 µg/mL
Third dosing interval (150 mg SC w16–28): 1.88 ± 1.34 µg/mL
| AUCτ First dosing interval (150 mg SC w0–4): 215 ± 69.9 µg*day/mL
Second dosing interval (150 mg SC w4–16): 608 ± 252 µg*day/mL
Third dosing interval (150 mg SC w16–28): 482 ± 218 µg*day/mL
| Vc: 4.71 (RSE 12.7) L IIV: 0.171 (RSE 43.2%) VP: 4.26 (RSE 5.9%) L
VSS: 11.1 L
| 0.248 (RSE 6.2%) L/day
Q: 0.839 (RSE 8.2%) L/day
IIV: 0.0943 (RSE 31.4%)
| CLBW: 0.869 (RSE 5.1%)
VC_BW: 1.46 (RSE 9.7%)
CLALB: -0.703 (RSE 17.2%)
CLCreatinine: -0.201 (RSE 18.3%)
CLCRP: 0.0471 (RSE 12.9%)
CLAge: -0.138 (RSE 21.2%)
None of the covariates mentioned above had a clinically meaningful effect.
|
Suleiman et al. (2023) (5) | Healthy subjects, and moderately to severely active CD.
| Two-compartment model with first-order absorption and elimination.
| First dosing interval (600 mg IV w0-4): 136 ± 93.2 µg/mL Second dosing interval (600 mg IV w4-8): 160 ± 99.4 µg/mL
Third dosing interval (600 mg IV w8-12): 171 ± 104 µg/mL
Steady state maintenance dosing interval (360 mg SC w40-48): 29.9 ± 16.9 µg/mL
| First dosing interval (600 mg IV w0-4): 24.9 ± 10.3 µg/mL
Second dosing interval (600 mg IV w4-8): 35.9 ± 17.5 µg/mL
Third dosing interval (600 mg IV w8-12): 41.0 ± 22.6 µg/mL
Steady state maintenance dosing interval (360 mg SC w40-48): 9.19 ± 11.1 µg/mL
| AUCτ
First dosing interval (600 mg IV w0-4): 1424 ± 432 µg*day/mL Second dosing interval (600 mg IV w4-8): 1896 ± 659 µg*day/mL
Third dosing interval (600 mg IV w8-12): 2111 ± 820 µg*day/mL
Steady state maintenance dosing interval (360 mg SC w40-48): 1043 ± 721 µg*day/mL
| VC: 4.98 (RSE 3.76%) L
VP: 2.70 (RSE 2.12%)
| 0.296 (RSE 1.55%) L IIV: 0.109 (RSE 20.7%)
Q: 0.255 (RSE 4.20%) L/day
| CLBW: 0.437 (RSE 13.2%)
VC_BW: 0.911 (RSE 15.8%)
CLAlbumin: -1.28 (RSE 5.08%)
CLCalprotectin: 0.0482 (RSE 13.6%) CLCorticosteroids: 0.0661 (RSE 14.3%)
CLCreatinine: 0.180 (RSE 17.5%)
CLSex: -0.0723 (RSE 20.7%)
None of the covariates mentioned above are expected to have a clinically relevant impact.
|
Thakre et al. (2024) (6)
| UC.
| Two-compartment model.
| First induction dosing interval (1200 mg IV w0-4): 290 ± 118 µg/mL Second induction dosing interval (1200 mg IV w4-8): 343 ± 128 µg/mL
Third induction dosing interval (1200 mg IV w8-12): 367 ± 134 µg/mL
Steady-state maintenance dosing interval (w40-48) for 180 mg SC q8w: 20.4 ± 6.96 µg/mL
Steady-state maintenance dosing interval (w40-48) for 360 mg SC q8w: 40.9 ± 13.9 µg/mL
| First induction dosing interval (1200 mg IV w0-4): 54.0 ± 18.1 µg/mL Second induction dosing interval (1200 mg IV w4-8): 79.0 ± 29.8 µg/mL
Third induction dosing interval (1200 mg IV w8-12): 91.1 ± 36.9 µg/mL
Steady-state maintenance dosing interval (w40-48) for 180 mg SC q8w: 5.00 ± 2.61 µg/mL
Steady-state maintenance dosing interval (w40-48) for 360 mg SC q8w: 10.0 ± 5.22 µg/mL
| AUCτ First induction dosing interval (1200 mg IV w0-4): 3053 ± 822 µg*day/mL
Second induction dosing interval (1200 mg IV w4-8): 4099 ± 1188 µg*day/mL
Third induction dosing interval (1200 mg IV w8-12): 4595 ± 1419 µg*day/mL
Steady-state maintenance dosing interval (w40-48) for 180 mg SC q8w: 633 ± 217 µg*day/mL
Steady-state maintenance dosing interval (w40-48) for 360 mg SC q8w: 1267 ± 435 µg*day/mL
| VC: 4.56 (RSE 4.55%) L
IIV: 0.382 (CV 68.2)
VP: 2.79 (RSE 2.98%) L
| 0.269 (RSE 1.61%) L/day
Q: 0.254 (RSE 5.40%) L/day
IIV: 0.0771 (CV 28.3%)
| CLBW: 0.679 (RSE 6.62%) VC_BW: 1.10 (RSE 11.6%)
CLALB: −1.21 (RSE 5.75%)
CLfcal: 0.0164 (RSE 33.1%)
CLfemale_compared_to_male: −0.0806 (RSE 17.4%)
CLcorticosteroid_use: 0.0334 (RSE 19.6%)
CLbaseline_CRP: 0.0396 (RSE 14.1%)
CLbaseline_pancolitis_no_compared_to_yes: −0.0557 (RSE 23.2%)
CLadvanced_therapy inadequate_response_no compared_to_yes: −0.116 (RSE 12.4%)
Only albumin had a clinically relevant effect.
|
| Abbreviations: ADA, anti drug antibodies; ALB, albumin; AUC, area under the concentration time curve; AUCτ, area under the plasma concentration–time curve over a dosing interval; AUC∞, area under the plasma concentration–time curve from time zero to infinity; BW, body weight; Cmax, maximum serum concentration; CL, clearance; CRP, c-reactive protein; CV, coefficient of variation; IIV, interindividual variability; kg, kilograms; L, liter; mg, milligrams; n, number; NR., not reported; PASI, psoriasis area and severity index; PK, pharmacokinetic; popPK, population pharmacokinetics; PsO, psoriasis; PPP, palmoplantar pustulosis; q, every; Q, intercompartmental clearance; RSE%, relative standard error percentage; SC, subcutaneously; SEE%, percent standard error of the estimate; Tmax, time to maximum concentration; Vd, volume of distribution; Vp, peripheral volume of distribution; Vz, volume of distribution during the terminal phase; w, week. |
Conclusion
This systematic review highlights limited availability of PK data and lack of sub-phenotype-specific studies for IL-23p19-inhibitors in IBD. Additionally, data on covariates influencing drug exposure in IBD are also scarce, both of which hinder the development of optimal dosing strategies for individual patients. These findings highlight the need for further research to better define PK parameters and influencing covariates, enabling personalized dosing strategies for IL-23p19-inhibitors in IBD, as well as in other IMIDs.
References
1 Suleiman AA, Khatri A, et al. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials. Clin Pharmacokinet 2019; 58: 375–87.
2 Suleiman AA, Minocha M, et al. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials. Clin Pharmacokinet 2019; 58: 1309–21.
3 Khatri A, et al. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. The Journal of Clinical Pharmacology 2019; 59: 1656–68.
4 Thakre N,
et al. Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther 2022; 9: 1587–603.
5 Suleiman AA,
et al. Population Pharmacokinetic and <scp>Exposure–Response</scp> Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn’s Disease. Clin Pharmacol Ther 2023; 113: 839–50.
6 Thakre N, et al. Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis. Clin Pharmacol Ther 2024; 116: 847–57.
Disclosure
The first author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated. ADEG: received speaker’s fees from AbbVie and Ferring, outside the submitted work. RJK is shareholder of Insight RX, San Francisco, CA, USA. MCD reports receiving consultancy and advisory fees from AbbVie, Abivax, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Meyer Squibb, Celltrion, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Johnson and Johnson, Merck, Pfizer Inc, Prometheus Labs, Sanofi, Spyre, and Takeda Pharmaceuticals, and licensing fees from Takeda Pharmaceuticals. JT has received consulting/advisory board fees from Abbvie, Pfizer, Janssen, Tillots Pharma, Takeda, Sandoz and Lilly; grant support from Janssen and Abbvie. RA has served as a speaker, consultant, or received research grants from AbbVie, Abivax, AlfaSigma, AstraZeneca, Bristol-Myers Squibb, Celltrion Healthcare, Galapagos, Johnson & Johnson, Lilly, MSD Sharp & Dohme, Pfizer, and Takeda Pharma. PMa is a full-time employee of Ionis and may hold Ionis stock or options. ED received consultancy fees from Alimentiv and Argenx; lecture fees from Celltrion and Galapagos; and financial support from Celltrion, Janssen, Pfizer, Prometheus Biosciences, R-Biopharm, and Sandoz, outside the submitted work, with all honoraria/fees being paid to KU Leuven and not to any personal account of ED. GD received a grant from Royal DSM, advisory board fees from Pharmacosmos and Astra-Zeneca, and speakers fee from Abbvie. HJV received grants paid to the University Medical Center Groningen from Albireo/Ipsen and Mirum and consultancy fees paid to the University Medical Center Groningen from Albireo/Ipsen, Intercept, Mirum, Orphalan, ProQR and Vertex, all outside of the submitted work. ARB reports receiving research grants from Janssen Pharmaceuticals and received speaker’s fees from AbbVie and Ferring Pharmaceuticals, outside the submitted work. All other authors have no conflicts of interest to declare.